Catherine S. Manno
University of Pennsylvania
65 Papers
543 Citations
Catherine S. Manno is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Haemophilia. The author has an hindex of 27, co-authored 64 publications. Previous affiliations of Catherine S. Manno include Cardiovascular Institute of the South & Virginia Commonwealth University.
Chat about Author
Papers
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Catherine S. Manno,Glenn F. Pierce,Valder R. Arruda,Bertil Glader,Margaret V. Ragni,Rasko Jj,Margareth C. Ozelo,Keith Hoots,Blatt P,Barbara A. Konkle,Michael D. Dake,Robin D. Kaye,Mahmood K. Razavi,A Zajko,James L. Zehnder,Pradip Rustagi,Hiroyuki Nakai,A Chew,Debra G.B. Leonard,Debra G.B. Leonard,J F Wright,Ruth Lessard,Jurg M. Sommer,Michael Tigges,Denise E. Sabatino,A Luk,Haiyan Jiang,Federico Mingozzi,Linda B. Couto,Hildegund C.J. Ertl,Katherine A. High,Katherine A. High,Mark A. Kay +32 more
TL;DR: In this article, a single portal vein infusion of a recombinant adeno-associated viral vector (rAAV) expressing canine Factor IX (F.IX) resulted in long-term expression of therapeutic levels of F.IX in dogs with severe hemophilia B.
2.1K
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
Mark A. Kay,Catherine S. Manno,Catherine S. Manno,Margaret V. Ragni,Peter J. Larson,Peter J. Larson,Linda B. Couto,Alan McClelland,Bertil Glader,Amy J. Chew,Shing J Tai,Roland W. Herzog,Valder R. Arruda,Fred Johnson,Ciaran Scallan,Erik D. Skarsgard,Alan W. Flake,Alan W. Flake,Katherine A. High,Katherine A. High +19 more
TL;DR: Evidence of gene expression at low doses of vector suggests that dose calculations based on animal data may have overestimated the amount of vector required to achieve therapeutic levels in humans, and that the approach offers the possibility of converting severe haemophilia B to a milder form of the disease.
1.1K
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
Catherine S. Manno,Amy J. Chew,Sylvia Hutchison,Peter J. Larson,Roland W. Herzog,Valder R. Arruda,Shing Jen Tai,Margaret V. Ragni,Arthur A. Thompson,Margareth C. Ozelo,Linda B. Couto,Debra G.B. Leonard,Fred Johnson,Alan McClelland,Ciaran Scallan,Erik D. Skarsgard,Alan W. Flake,Mark A. Kay,Katherine A. High,Bertil Glader +19 more
TL;DR: Results of the first parenteral administration of rAAV demonstrate that administration of AAV vector by the intramuscular route is safe at the doses tested and effects gene transfer and expression in humans in a manner similar to that seen in animals.
799
CD8(+) T-cell responses to adeno-associated virus capsid in humans.
Federico Mingozzi,Marcela V. Maus,Marcela V. Maus,Daniel J. Hui,Denise E. Sabatino,Samuel L. Murphy,John E.J. Rasko,John E.J. Rasko,Margaret V. Ragni,Catherine S. Manno,Catherine S. Manno,Jurg M. Sommer,Haiyan Jiang,Glenn Pierce,Hildegund C.J. Ertl,Katherine A. High,Katherine A. High,Katherine A. High +17 more
TL;DR: It is shown that healthy subjects carry AAV capsid–specific CD8+ T cells and that AAV-mediated gene transfer results in their expansion, and that no such expansion occurs in mice after A AV- mediated gene transfer.
730
Dose of prophylactic platelet transfusions and prevention of hemorrhage.
Sherrill J. Slichter,Richard M. Kaufman,Susan F. Assmann,Jeffrey McCullough,Darrell J. Triulzi,Ronald G. Strauss,Terry Gernsheimer,Paul M. Ness,Mark E. Brecher,Cassandra D. Josephson,Barbara A. Konkle,Robert D. Woodson,Thomas L. Ortel,Christopher D. Hillyer,Donna Skerrett,Keith R. McCrae,Steven R. Sloan,Lynne Uhl,James N. George,Victor M. Aquino,Catherine S. Manno,Janice G. McFarland,John R. Hess,Cindy A. Leissinger,Suzanne Granger +24 more
TL;DR: Low doses of platelets administered as a prophylactic transfusion led to a decreased number of platelet transfused per patient but an increased number of transfusions given.